An observational study in Sezary Syndrome and Cutaneous T Lymphoma, sponsored by Assistance Publique - Hôpitaux de Paris. Status unknown at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-01-25.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Sezary syndrome (SS) is a rare, aggressive and advanced form of cutaneous T lymphoma with a poor prognosis (5-year survival rate varying between 24% and 52%). The treatments are only suspensive with short-term remissions. For the past fifteen years, therapeutic approaches have been based on depleting monoclonal antibodies (anti-CD52, anti-CCR4, anti-KIR3DL2, anti-CD70), or antibody-drug conjugates (anti-CD30). But while the efficacy of mogamulizumab on progression-free survival was reported in the phase III study, no study on a large cohort has compared the current overall survival of patients with Sezary syndrome to that before the era of monoclonal antibodies. In this context, we propose to report a large series of patients with Sézary syndrome in order to compare the current survival of patients with that of the pre-monoclonal antibodies era (1998-2003).
The objective of this study is to assess the evolution of the overall survival of patients with Sezary syndrome since the early use of therapeutic monoclonal antibodies. The underlying hypothesis of this study is that the use of therapeutic monoclonal antibodies has improved the prognosis of these patients. Patients included in this retrospective study are patients with a Sezary syndrome diagnosed between 1998 and 2020.
164 studies on the registry are indexed under Sezary Syndrome; 21 are open to participants now.
This study's planned enrollment of 700 is above the median of 120 across 19 observational studies indexed under Sezary Syndrome.
Browse Sezary Syndrome studies →Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,505 studies on the registry; 1,006 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adult patient with Sézary syndrome diagnosed between 1998 and 2020
Exclusion Criteria:
Adult patient with Sezary syndrome diagnosed between 1998 and 2020
Other: Standard of care
Standard of care for patients with Sezary Syndrome
Overall Survival
Time frame: at 5 years
Overall survival
Time frame: at 10 years
Overall survival
Time frame: at 15 years
Sezary syndrome specific survival
Time frame: at 5 years
Sezary syndrome specific survival
Time frame: at 10 years
Sezary syndrome specific survival
Time frame: at 15 years
Plan to share: Undecided
No publications or documents are linked to this record.
This study is status unknown, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris